Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: Results of 1,870 Chinese patients with thyroid nodules

Endocrine Journal

Volumn 59, Issue 11, 2012, Pages 973-980

  Shi, Lei ^a   Li, Yushu ^a   Guan, Haixia ^a   Li, Chenyan ^a   Shi, Liangfeng ^a   Shan, Zhongyan ^a   Teng, Weiping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Differentiated thyroid cancer; Microcarcinoma; Risk factor; Thyrotropin

Indexed keywords

THYROID ANTIBODY; THYROTROPIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CHILD; CHINESE; COHORT ANALYSIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY; SCHOOL CHILD; THYROID CANCER; THYROID NODULE; THYROID SURGERY; THYROTROPIN BLOOD LEVEL; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; CHINA; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE; THYROTROPIN;

EID: 84871063878     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0154     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
2. Simard EP, Ward EM, Siegel R, Jemal A (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012 Jan 4. doi: 10.3322/caac.20141. [Epub ahead of print]
3. Chen AY, Jemal A, Ward EM (2009) Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115:3801-3807.
4. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds) SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/,based on November 2006 SEER data submission, posted to the SEER web site, 2007.
5. Cairong Zhu, Tongzhang Zheng, Briseis A. Kilfoy, Xuesong Han, Shuangge Ma, Yue Ba, Yana Bai, Rong Wang, Yong Zhu, Yawei Zhang (2009) A Birth Cohort Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 1973-2004. Thyroid 19: 1061-1066.
6. Guan H, Shan Z, Mi X, Wang E, Teng W (2006) Incidence of thyroid carcinoma before and after universal salt iodization: an 11-year retrospective analysis of pathological reports. J Chin Med Univ 35: 284-285 (In Chinese).
7. Mazzaferri EL. An overview of the management of thyroid cancer. In: 2006; Mazzaferri EL, Harmer C, Mallick UK, Kendall-Taylor P, eds. Practical Management of Thyroid Cancer: A Multidisciplinary Approach. London, England: Springer-Verlag; 1-28.
8. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83: 2638-2648.
9. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167-1214.
10. Hegedüs L (2004) Clinical practice. The thyroid nodule. N Engl J Med 351:1764-1771.
11. Fiore E, Vitti P (2012) Serum TSH and Risk of Papillary Thyroid Cancer in Nodular Thyroid Disease. J Clin Endocrinol Metab 97:1134-1145.
12. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA (2006) Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 91:4295-4301.
13. Fiore E, Rago T, Provenzale A, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, Pinchera A, Vitti P (2009) Lower levels of TSH are associated to a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer 16:1251-1260.
14. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Miccoli P, Grasso L, Pinchera A, Vitti P (2010) L-Thyroxine treated patients with nodular goiter have lower serumTSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27,914 patients. Endocr Relat Cancer 17:231-239.
15. Rago T, Fiore E, Scutari M, Santini F, Di Coscio G, Romani R, Piaggi P, Ugolini C, Basolo F, Miccoli P, Pinchera A, Vitti P (2010) Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. Eur J Endocrinol 162:763-770.
16. Kim KW, Park YJ, Kim EH, Park SY, Park do J, Ahn SH, Park do J, Jang HC, Cho BY (2011) Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck 33:691-695.
17. Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, Scutari M, Basolo F, Di Coscio G, Grasso L, Pinchera A, Vitti P (2011) Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 18:429-437.
18. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93:809-814.
19. Gerschpacher M, Göbl C, Anderwald C, Gessl A, Krebs M (2010) Thyrotropin serum concentrations in patients with papillary thyroid microcancers. Thyroid 20:389-392.
20. Guan H, Li C, Li Y, Fan C, Teng Y, Shan Z, Teng W (2005) High iodine intake is a risk factor of post-partum thyroiditis: result of a survey from Shenyang, China. J Endocrinol Invest 28: 876-881.
21. Guan H, Shan Z, Teng X, Li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, Yang F, Dai H, Yu Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, Chen W, Tong Y, Wang W, Gao T, Li C, Teng W (2008) Influence of iodine on the reference interval of TSH and the optimal interval of TSH: results of a follow-up study in areas with different iodine intakes. Clin Endocrinol (Oxf) 69:136-141.
22. Li Y, Teng D, Shan Z, Teng X, Guan H, Yu X, Fan C, Chong W, Yang F, Dai H, Gu X, Yu Y, Mao J, Zhao D, Li J, Chen Y, Yang R, Li C, Teng W (2008) Antithyroperoxidase and antithyroglobulin antibodies in a five-year follow-up survey of populations with different iodine intakes. J Clin Endocrinol Metab 93:1751-1757.
23. Lim AK, Daykin J, Holder R, Sheppard MC, Franklyn JA (1998) Measurement of serum TSH in the investigation of patients presenting with thyroid enlargement. QJM 91:687-689.
24. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H (2009) Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 71:434-439.
25. Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D, Flaris N, Leontsini M, Kourtis A, Avramidis A (2008) Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol 134: 953-960.
26. Jonklaas J, Nsouli-Maktabi H, Soldin SJ (2008) Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid 18:943-952.
27. Jin J, Machekano R, McHenry CR (2010) The utility of preoperative serum thyroid- stimulating hormone level for predicting malignant nodular thyroid disease. Am J Surg 199: 294-297.
28. Castro MR, Espiritu RP, Bahn RS, Henry MR, Gharib H, Caraballo PJ, Morris JC (2011) Predictors of malignancy in patients with cytologically suspicious thyroid nodules. Thyroid 21: 1191-1198.
29. Kim SS, Lee BJ, Lee JC, Song SH, Kim BH, Son SM, Kim IJ, Kim YK, Kang YH (2011) Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: a single-center experience. Endocrine 39:259-265.
30. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA (2011) Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108:1615-1620.
31. Derwahl M, Broecker M, Kraiem Z (1999) Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab 84: 829-834.
32. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489-499.